Michael Douglas Cancer: Throat Tumor Treatment For Catherine Zeta-Jones Husband

Aaron M. | August 17, 2010 | 1 Comment More

Michael Douglas Cancer: Throat Tumor Treatment For Catherine Zeta-Jones Husband – It has been announced that Michael Douglas is to receive treatment for a tumour in his throat that has grown and is causing him some health problems.

Douglas, 65, an Academy Award winner, will undergo radiation and chemotherapy to remove the tumour from his throat. This is expected to last about 8 weeks of treatment, after which he is expected to make a full recovery. He told People magazine in a statement Monday he’s “very optimistic.” His publicist’s assistant, Eli Barach, confirmed his condition to The Associated Press.

Where he will be treated though hasn’t been released, obviously during this time Douglas is looking to have no media attention, and wishes to avoid a media circus. Currently, he is outside of the U.S., but where exactly is unknown, according to his publicist Allen Burry said on Monday. His location and where he will be treated are both unknown and not to be released.

Currently, his wife Catherine Zeta-Jones and Douglas own a home on the island of Bermuda, which they have owned for almost a decade. They plan to raise to children, of which they have, there to keep them out of the media spotlight that surrounds Hollywood and the famous.

Be Sociable, Share!

Category: Health News

Leave a Reply

Comments (1)

Trackback URL | Comments RSS Feed

  1. Juliaqn Lieb,M.D says:

    THE REMARKABLE ANTICANCER PROPERTIES OF ANTIDEPRESSANTS
    Oncology is in desperate need of a paradigm shift. The shift dates back to 1981, when I published the first of nine reviews on the remarkable, immunostimulating and antimicrobial properties of lithium and antidepressants, and culminated in 2001 with publication of the first of five articles on the anticancer properties of antidepressants. Innumerable vested interests have prevented the paradigm shift from reaching the bedside.
    The idea that antidepressants might be effective for cancer was first explored fifty years ago, and ample proof has emerged. To verify, access Medline or Pubmed, and enter “antidepressants” and “cancer.” With patience, you may retrieve more than seventy studies showing that antidepressants destroy cancer cells, inhibit their proliferation, convert multidrug resistant cells to chemotherapy sensitive, protect nonmalignant cells from damage by ionizing radiation and chemotherapy toxicity, and target the mitochondria of cancer cells, while sparing those of healthy ones. Antidepressants can arrest cancer even in advanced stages, occasionally reverse it, significantly extend life, and have shown effectiveness in malignancies often resistant to chemotherapy and radiation. In 1998, Brenda Penninx showed that at age 70, people who are chronically depressed have an increased risk of cancer of 88%, and an increased risk of dying of it of 50%.
    Paradigm shifts may not become medical revolutions unless widely disseminated, so as to bypass vested interests. This one could do wonders for people, and for health economics. I have contributed five reviews and two books to the advance.

    Lieb, J. “Antidepressants, eicosanoids and the prevention and treatment of cancer.” Plefa (2001) 65(5&6), 233-239

    Lieb, J. “Antidepressants, prostaglandins and the prevention and treatment of
    cancer.” Medical Hypotheses (2007) 684-689

    Lieb, J.”The multifaceted value of antidepressants in cancer therapeutics.” Editorial comment. European Journal of Cancer 44 (2) 2008 172-174

    Lieb, J.”Defeating cancer with antidepressants.” Ecancermedicalscience. DOI 10.3332/eCMS.2008.88

    Lieb, J.”The remarkable anticancer properties of antidepressants.” DOI.10.3332/eCMS.LTR.149

    Lieb, J.”Stimulating immune function to kill viruses.” (2009) Amazon
    Lieb, J.”Killing Cancer” (2010) Amazon
    A clinical experience with Mianserin therapy in lung cancer patients
    .Two groups of advanced non-small cell lung cancer (NSCLC) were analyzed and compared: Group A-26 patients (12 treated with chemotherapy –CT, 14 with best supportive care BSC), all receiving 10mg/day of Mianserin and Group B-26 patients with comparable corresponding characteristics, who were treated with chemotherapy.
    An objective clinical response to chemotherapy was observed in five patients receiving Mianserin, and only two patients who did not receive it. Median survival time for Mianserin patients was also significantly better. A surprising fact emerged in 2 patients with adenocarcinoma: one with local tumor recurrence and diffuse bone metastases, evidently stable with no further progression for 37 months, the other with metastases in the upper mediastinal lymph nodes, with no further progression for 26 months. Symptom control (pain, dyspnea, and emotional functioning) were significantly better in Mianserin Group A.

    Antidepressants are highly specific and humans variable, thus some of the non responders may well have responded to alternatives to Mianserin.

    Jovanovic D, et al Mianserin therapy in advanced lung cancer patients. 8th Central European Lung Cancer Conference. Vienna 2002. Internal Process Division, Monduzzi Editore 2002; 339-343